Verve Therapeutics 第四季度的收益超出预期，但在负面财务指标下，其股价跌至 6.20 美元。 Verve Therapeutics beat Q4 earnings estimates but saw its stock fall to $6.20 amid negative financial metrics.

Verve治疗公司是一家研制心血管疾病基因编辑药品的公司,它报告说,4Q EPS为0.58美元,击打估计数为0.14美元。 Verve Therapeutics, a company developing gene editing medicines for cardiovascular diseases, reported a Q4 EPS of ($0.58), beating estimates by $0.14. 尽管财务指标负面,包括35.23%的负利率和807.65%的负净利率,但股价下跌至6.20美元. Despite negative financial metrics, including a 35.23% negative ROE and an 807.65% negative net margin, the stock fell to $6.20. 该公司的主导产品VERVE-101瞄准PCSK9基因。 The company's lead product, VERVE-101, targets the PCSK9 gene. 分析师给予Verve“Buy”评分,平均目标价格为25.75美元。 Analysts give Verve a "Buy" rating with a $25.75 average target price.